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Abstract and Keywords 
Background: Magnetic Resonance Imaging (MRI) of pacemaker patients is 
contraindicated due to documented potential risks to the patient from hazardous 
interactions between the MRI and pacemaker system.  
Objective: This prospective, randomized controlled, worldwide clinical trial evaluated 
safety and effectiveness of a pacemaker system designed for safe use in MRI for any 
bradycardia indicated patient.  
Method: Patients (n=464) were randomized to undergo an MRI scan between 9-12 
weeks post-implant (MRI group, n=258) or not to undergo MRI (control group, n=206) 
after successful implantation of the specially designed dual chamber pacemaker and 
leads. Patients were monitored for arrhythmias, symptoms and pacemaker system 
function during 14 non clinically indicated relevant brain and lumbar MRI sequences.  
Sequences were performed at 1.5 Tesla (T) and included scans with high radiofrequency 
power deposition and/or high gradient dB/dt exposure.  Clinical evaluation of the 
pacemaker system function occurred immediately before and after MRI, 1-week and 1-
month post-MRI and at corresponding times for the control group.   Primary endpoints 
for safety analyzed the MRI procedure complication-free rate, and for effectiveness 
compared capture and sensing performance between MRI and control groups. 
Results: No MRI-related complications occurred during or after MRI, including 
sustained ventricular arrhythmias, pacemaker inhibition or output failures, electrical 
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resets or other pacemaker malfunctions.  Pacing capture threshold and sensed electrogram 
amplitude changes were minimal and similar between study groups. 
Conclusion: This trial documented the pacemaker system’s ability to be exposed in a 
controlled fashion to MRI in a 1.5T scanner without adverse impact on patient outcomes 
or pacemaker system function. 
Keywords: Bradycardia pacing, CapsureFix MRI™ Model 5086MRI, EnRhythm 
MRI™, MRI, Safety, SureScan™, Pacemaker, Revo MRI™
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Introduction 
Safe Access to MRI is a Critical Need for Pacemaker Patients 
The use of Magnetic Resonance Imaging (MRI) as the imaging modality of choice in 
many fields (e.g. brain, spinal cord and musculoskeletal system) is rapidly increasing. 
However, manufacturers of cardiac devices and of MRI systems contraindicate MRI for 
patients with implanted pacemaker systems due to multiple associated risks. 
Approximately 5,000,000 patients worldwide are currently implanted with a pacemaker 
or implantable cardioverter defibrillator (ICD) and at least 50% of these patients are 
expected to be indicated to undergo clinical MRI over the lifetime of their device.
1
 
Risks associated with MRI scans of pacemaker patients 
Literature documents that there are several interactions between the MRI associated static 
magnetic field, gradient fields and radiofrequency (RF) field and the implanted 
pacemaker system may be hazardous to the patient and/or damage the device. 
2-4
  Despite 
the potential for adverse outcomes, a few centers perform MRI scanning of carefully 
selected pacemaker patients using precautions when the benefit outweighs the risk. Even 
in these centers and under extensive expert supervision, clinically significant irregular 
pacemaker system behavior cannot always be prevented or good patient outcomes 
assured.
 5
 
 A pacemaker system (EnRhythm MRI™ SureScan™ Implantable Pulse Generator 
(IPG) and CapSureFix MRI™ leads (Model 5086MRI leads) used in support for Revo 
MRI SureScan pacing system, Medtronic, Inc., Minneapolis, MN) designed specifically 
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to mitigate these hazards provides access to pacemaker patients for this important 
diagnostic modality. The aim of the trial was to evaluate safety and efficacy of this novel 
pacemaker system during MRI in a prospective, randomized, multicenter trial. 
Methods 
Pacemaker system  
The following design modifications were made to the pacemaker system to improve MRI 
compatibility: 1) The leads were modified to reduce RF lead tip heating, 2) Internal 
circuits were changed to reduce the potential for cardiac stimulation, 3) The amount of 
ferromagnetic materials was limited, 4) Internal circuit protection was improved to 
prevent disruption of the internal power supply, 5) The reed switch was replaced by a 
Hall sensor, whose behavior in a static magnetic field is predictable and 6) A dedicated 
programming care pathway was developed to facilitate the choice between asynchronous 
versus non-stimulation modes, increase the pacing output to 5.0V / 1.0 ms during MRI 
scanning, prevent programming the MRI mode if the device fails any of the 10 system 
integrity checks and facilitate restoration of pre-scan program states and values. (Table 1)  
 Conditions for safely scanning patients with this system during this trial required a 
static magnetic field strength of 1.5T, a maximum Specific Absorption Rate (SAR) value 
of 2W/kg for each sequence and a maximum gradient slew rate of 200T/m/s.  
Furthermore, the position of the isocenter of the RF transmitter coil must be above the 
superior surface of the C1 vertebra or below the inferior surface of the body of T12.   
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Trial design and patient selection 
This was a prospective, randomized controlled, multicenter clinical trial with centers in 
the United States, Canada, Europe and the Middle East (ClinicalTrials.gov identifier 
NCT00433654).
6
 The trial was performed in accordance with the Declaration of Helsinki 
and to laws and regulations of the countries which participated. Each center had Medical 
Ethics Committee approval of the trial protocol and each patient had written informed 
consent prior to enrollment. Patients were enrolled who met Class I or II dual chamber 
pacemaker implant indications according to ACC/AHA/HRS guidelines
7
 (either 
pacemaker dependent or non-pacemaker dependent) and were able and willing to 
undergo a non clinically indicated MRI scan without intravenous sedation, had no 
implanted non-MRI compatible devices or materials, no other implantable active medical 
devices and no abandoned leads. 
Data collection and analysis 
After a successful pacemaker and lead implantation, randomization was performed to 
either undergo an MRI scan (MRI group) or not to undergo an MRI scan (Control) at 9-
12 weeks after system implantation. Initially patients were randomized 1:1 but later 
changed to 2:1 to meet the regulatory requirement for >200 scanned patients. Follow-up 
visits are summarized in Figure 1. The 9-12 week visit consisted of an evaluation 
immediately before (pre-MRI evaluation), during (MRI) and directly after the MRI (post-
MRI evaluation) as well at the corresponding time points for the control group. During 
these evaluations, pacemaker performance, including assessment of pacing capture 
threshold (PCT) at a pulse duration of 0.5ms, sensed electrogram amplitude and lead 
impedance, were performed. Technical observations and adverse events were evaluated, 
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including sustained ventricular arrhythmias, pacemaker output inhibition, asystole, 
electrical reset, and pacemaker function during and after the MRI scan. Data stored 
within the pacemaker, rhythm strips during PCT testing and case report forms were 
collected.  
MRI 
The MRI scans were performed with 1.5T systems from three MRI manufacturers 
(General Electric, Philips and Siemens). The body coil served as the RF transmit coil. 
Fourteen MRI head and lumbar spine sequences were performed.  Total MRI 
investigation time was approximately 60 minutes (static magnetic field exposure) with a 
total active MRI scanning time of approximately 30 minutes (gradient and RF field 
exposure). MRI scanning protocol represented clinically relevant scans with a maximized 
gradient slew rate up to 200T/m/s and/or a maximized transmitted RF power up to SAR 
levels of 2W/kg body weight (upper limit of normal operating mode). Due to the MRI 
interference, electrocardiographic monitoring provided inaccurate assessments of heart 
rate and rhythm.  Instead, pulse oximetry provided the ability to continuously monitor 
heart rate and oxygen saturation and was not affected by the MRI fields. Patients were 
also monitored using verbal communication and when available, non-invasive blood 
pressure monitoring. 
Statistics 
To assess if the MRI related complication-free rate in the month following the MRI was 
greater than 90%, a one-sided one-sample exact test of binomial proportions along with a 
one-sided 97.5% confidence interval (CI) were calculated.  
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The proportion of patients who experienced a change in PCT of ≤0.5V at 0.5ms from 
before the MRI/control visit to the1-month post visit were tested for equivalence between 
MRI and control groups by using a two-sample 97.5% confidence interval, with 
Farrington-Manning p-values. The equivalence margin was 10%. The proportion of 
patients who experienced a change in sensing amplitudes from before the MRI/control 
visit to the 1-month post visit were tested for statistical equivalence between the MRI and 
control group by two-sample one-sided 97.5% CI, with p-values from the Farrington-
Manning test for equivalence of proportions. Success was achieved if the sensing 
amplitude decreased less than or equal to 50% and the amplitude remained above a 
clinically acceptable minimum of 1.5mV in the atrium or 5.0mV in the ventricle.  
Pre-specified analysis exclusion criteria were listed in the protocol. Additional analyses 
were performed to include excluded data from the PCT and sensing analyses.  
The proportion of patients free of system-related complications related from implant until 
1-month post-MRI/control visit was compared to a value of 80% by a one-sided one-
sample exact test with one-sided 95% CI. 
Statistics were performed by Medtronic and re-evaluated by the Cleveland Clinic 
Coordinating Center for Clinical Research (C5 Research), Cleveland, OH, US. 
Adverse Event Classification 
All adverse events were classified in several ways by an adverse events committee: 
according to their relationship to the implant procedure, to the MR procedure, and to the 
pacing system.  In some cases, adverse events were classified as having an unclear 
relationship to the implant, MR or pacing system due to the inability to assign the 
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component of the system or procedure. In addition, adverse events were classified as 
either complications or observations. The definition of a complication was predefined as 
an adverse event that resulted in an invasive intervention or the termination of significant 
device function. The definition of an observation was predefined as an adverse event that 
was not a complication.  
Independent data monitoring, MRI scan advisory, and adverse events committees 
reviewed information and provided recommendations. 
Results 
Trial population 
A total of 464 patients were randomized after successful pacemaker system implantation 
between February 2007 and August 2008 (258 to the MRI group and 206 to the control 
group).  A summary of the distribution of patient enrollments, follow-up by randomized 
group, and inclusion and exclusion of data are listed in Figure 1. The mean follow-up 
time was 11.2±5.2 months (range 0.1-21.5 months). The patient characteristics were 
typical of pacemaker patients and are listed in Table 2 Error! Reference source not 
found..   
Safety 
A total of 211 patients had an MRI performed per protocol instructions and completed the 
1-month post-MRI/control visit. There were no MRI-related complications through the 1-
month post-MRI/control visit and thus the proportion of patients free of MRI-related 
complications was 100% (211/211), with a one-sided 97.5% CI of 98.3%. When analyzed 
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against the comparison rate of 90%, the p-value is <0.001. In addition, none of the 
additional 16 patients who underwent any portion of the MRI scan: partial scan (n=6), 
exceeded maximum allowed SAR scan limits (n=8), exceeded pre-MRI evaluation 
capture threshold (high capture threshold, n=1), or control patient who inadvertently 
underwent an MRI scan (n=1), experienced MRI-related complications. 
 All MRI examinations (226/226, 100%, 95% CI 98.7-100%) were completed safely 
with continuous pacemaker stimulation when programmed to asynchronous mode 
(n=158), or regular spontaneous intrinsic activation when programmed to no pacing mode 
(n=67). One subject was scanned in an unknown mode.  Formal assessment of pacemaker 
dependency was not evaluated however 16 MRI and 11 control patients had no 
ventricular intrinsic rhythm at the pre 9-12 week assessment.  No inhibition of pacemaker 
output, asystole, sustained ventricular arrhythmias, unexpected changes of heart rate, or 
electrical resets occurred during MRI. No pacemaker system disturbances during or after 
MRI were observed. No sensation of torque or pain was reported during MRI.  
 While there were no MRI complications, there were eight observations which were 
either classified as being MRI related or unclear if related to the MRI procedure. Four 
patients reported paraesthesia (n=3) and palpitation symptoms (n=1), which were 
identified as related to the MRI, required no invasive actions and all resolved the same 
day as the MRI. These events are typical events seen among patients who receive MRIs. 
Another four patients reported mild transient chest pressure (n=1), swallowing problems 
(n=1), atrial flutter (n=1) and atrial fibrillation symptoms (n=1), which were assessed as 
having an unknown relationship to the MRI, but no relationship to the pacemaker system 
and required no invasive interventions.  
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 Over the course of the trial eleven deaths occurred, including nine in the MRI group. 
None were related to the MRI procedure, implantation procedure or pacemaker system. 
Three deaths occurred prior to the MRI exam, and six deaths occurred after the MRI 
exam (pulmonary edema related to renal failure, non-cardiac sepsis, myocardial 
infarction, stroke, acute ischemic stroke and cardiac failure occurred 10, 43, 193, 299, 
402 and 461 days after the MRI procedure, respectively). The discrepancy between MRI 
and control deaths appears to be a statistical variant, with no clear relationship of mode of 
death. 
 The proportion of patients free of pacemaker system-related complications through 
the 1-month post-MRI/control visit was expected to be greater than 80% and was  
measured to be 91.7% (410/447), with a one-sided 95% CI of 89.3% (p<0.001).  A total 
of 37 patients experienced 43 system-related complications exhibited as lead 
dislodgement (n=17), elevated capture thresholds (n=9), pericardial effusion (n=3) and 
failure to capture (n=3).  None of these were related to MRI. 
Pacing capture threshold equivalence 
The proportions of patients in the MRI and control group who experienced an increase in 
PCT ≤ 0.5V from directly before the MRI/control visit to the 1-month post visit were 
clinically and statistically equivalent. None of the atrial (165/165, MRI vs. 164/164, 
control) or ventricular lead (190/190, MRI vs. 183/184, control) PCT patients 
demonstrated an increase of >0.5 V and only one of the ventricular control patients 
increased 1.0 V.  PCT was 5 V prior to and 6V one-month after the 9-12 week control 
evaluations and the lead was subsequently replaced. With both atrial capture success rates 
at 100%, the one-sided 97.5% confidence bound could not be calculated.  The upper 
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bound of the one-sided 97.5% confidence limit was 1.6% for the ventricular PCT changes 
(p≤ 0.001), indicating that the two groups are statistically comparable.  (Figure 2&3) 
The intention to treat analysis  included data from MRI scan deviations, late follow-up 
visits, and all available follow-up visits, the atrial threshold success rates were 200/200 in 
the MRI group (100%) and 177/177 (100%) in the control group. The ventricular 
threshold success rates were 224/225 in the MRI group (99.6%) and 194/195 (99.5%) in 
the control group. In one patient, the PCT increased from 1.5V before the MRI to 2V 
immediately after the MRI and to 2.5V at 1-month post-MRI visit.  In this patient PCT 
returned to 2V at the 12-month visit.  Also in this patient the SAR limit of 2 W/kg was 
exceeded for one lumbar scan sequence (2.5W/kg) when performing the full set of brain 
and lumbar scans, the only such instance in the eight patients in whom the SAR limit was 
exceeded. The upper bound of the one-sided 97.5% confidence limit was 1.4%. This 
additional analysis supported that the PCT success rates of the two groups were 
equivalent. 
Sensing equivalence 
There was clinical equivalence of the proportion of patients who maintained the sensed 
electrogram amplitudes above 1.5mV (atrial) or 5mV (ventricle) at 1-month post 
MRI/control visit and above 50% of the amplitude measured directly before the 
MRI/control visit as compared to the 1-month post-MRI/ control evaluation. The success 
rate for atrial sensing amplitude was 94.7% (124/131) in the MRI group and 92.8% 
(129/139) in the control group. The success rate for ventricular sensing amplitude was 
97.0% (130/134) in the MRI group and 94.9% (129/136) in the control group.  Sensing 
values below the 1.5mV (atrial) or 5.0mV (ventricle) at the 1-month post-MRI/control 
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visit were primarily the reasons for non-success. The upper bounds of the one-sided 
97.5% confidence limits were 7.6% (p≤0.001) for the atrial and 6.9% (p≤0.001) for the 
ventricle sensing amplitudes, indicating that the two groups are statistically comparable. 
(Figure 4)  
By intention to treat analysis, the success rates for atrial sensing amplitudes were 162/172 
in the MRI group (94.2%) and 141/151 (93.4%) in the control group.  The upper bound 
of the one-sided 97.5% confidence limit was 6.1%. The ventricular sensing success rates 
were 172/178 in the MRI group (96.6%) and 140/147 (95.2%) in the control group. The 
upper bound of the one-sided 97.5% confidence limit was 5.7%. In addition, all subjects 
with low sensing values (<1.5mV for atrial and <5.0mV for ventricular) just before the 
MRI/control visit were considered successful because the sensing amplitude decrease did 
not exceed 50%.  These additional analyses supported that the sensing amplitude success 
rates of the two groups were comparable.   
Impedance equivalence 
The impedance results did not exhibit change beyond expected variations with repeated 
measurements. (Figure 5) 
 Discussion 
This prospective, randomized controlled, multicenter trial evaluated safety and efficacy 
of a pacemaker system specifically designed to be used during MRI. No MRI-related 
complications, no disturbances of pacemaker function, and no ventricular arrhythmia 
induction were observed. PCT and sensing amplitude changes from immediately before 
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the MRI/control visit to the 1-month post visit were clinically equivalent between MRI 
and control groups. All pacemaker system-related complications were within an expected 
and clinically acceptable range.
8-10
  These results indicate that this pacemaker system can 
be used safely in an MRI environment when used in accordance with its labeling. 
RF-induced heating 
Heating of pacemaker leads during MRI has been shown to depend on numerous 
parameters including the amount of transmitted RF energy (quantified by the SAR), 
patient size and anatomy, patient position within the scanner bore, and the position of the 
pacemaker lead within the RF field.
11-14
 Furthermore, heating depends on the specific 
lead design and lead length. Variations among different lead models can result in 
different risks of lead tip heating.
15 
 
 Publications have shown that substantial increases in PCT 
16, 17
 and serum troponin
16
 
can be observed after MRI at 1.5T in patients implanted with conventional pacemakers. 
PCT changes have been attributed to RF-induced heating of the cardiac tissue in 
proximity to the pacemaker lead tip, resulting in thermal injury.
16, 
 These findings of 
potential RF-related thermal injury are further supported by in-vitro experiments
4, 18, 19
 
and in-vivo animal studies.
3, 4
 
 The leads of this new pacemaker system were modified to reduce lead tip heating 
from transmitted RF power. To be conservative and further minimize heating when 
performing an MRI scan with this new pacemaker system, centering the transmitting RF 
coil between C1 and T12 was precluded and the SAR value was restricted to ≤ 2W/kg. It 
should be noted that the positioning restriction (isocenter of the coil to a position outside 
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the area of the superior surface of C1 vertebra to the inferior surface of T12 vertebra) still 
permits scanning the complete cervical region and most, if not all, of the thoracic region 
by widening the field of view. The SAR value of ≤ 2W/kg is the upper limit of the 
Normal Operating Mode, which allows performance of the vast majority of clinically 
relevant MRI scans. 
 There was clinical equivalence for the proportions of patients in the MRI and control 
group who experienced PCT or sensing amplitude changes from directly before to 1-
month post-MRI/control visit. This is consistent with a lack of clinically relevant RF-
induced myocardial thermal damage induced by MRI in patients with this pacemaker 
system. 
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Unintended Cardiac Stimulation 
Gradient magnetic and RF electromagnetic fields produced by MRI scanners induce 
pulsed voltages in pacemaker leads that are conducted to the heart at the myocardial-
electrode interface. If these MRI-induced voltage pulses are large enough, they could 
directly stimulate the heart, which is known as unintended cardiac stimulation (UCS).  
Clinical manifestations of UCS due to single or multiple captured beats include 
palpitations or hemodynamic collapse and potentially fatal sustained ventricular 
tachycardia.  Out of 227 patients exposed to the MRI scanning protocol who were 
monitored via pulse oximetry, there were no UCS adverse events reported with 
relationship to the MRI procedure.  
Interference with pacemaker function 
In the strong static magnetic field of the MRI unit, the reed switch state (open or closed) 
and the pacemaker (synchronous or asynchronous) is not always predictable.
20
  If the 
pacemaker stays in synchronous mode during an MRI examination, the gradient field can 
mimic intrinsic cardiac electrical activity, and, thus, inhibit pacemaker output 
21
, which 
may be fatal for a pacemaker-dependent patient. On the other hand, fixed cardiac pacing 
in an asynchronous mode due to MRI-related closure of the reed switch may lead to 
competitive rhythms (intrinsic rhythm and fixed pacemaker stimulation), creating a risk 
of inducing possibly fatal tachyarrhythmias.
22, 23
  
The use of  a Hall sensor mitigates this risk, whose behavior in the MRI environment is 
predictable, and by including a specific MRI operation feature. With this feature, the Hall 
sensor is suspended and is not influenced by the static magnetic field; the physician can 
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choose either to program the pacemaker to an asynchronous pacing mode or to a non-
pacing mode. Asynchronous pacing will maintain appropriate pacing support throughout 
the MRI examination regardless of the noise sensed by the pacemaker system and 
without the risk of pacing output inhibition. For patients who are non-pacemaker 
dependent, the non-pacing mode is available.  
Electrical Reset 
An electrical reset is an emergency safety feature that guarantees minimal pacemaker 
functionality in case of battery voltage dips due to electromagnetic interference or battery 
depletion. An electrical reset will cause a change in the programmed parameters to basic 
settings, and to an inhibited pacing mode (VVI) with a manufacturer determined 
stimulation rate.  
 Previously, electrical reset has been reported on exposure to the MRI field in six 
percent of pacemaker patients undergoing MRI.
16
 An electrical reset has important safety 
implications: 1) When the reed switch remains open pacemaker inhibition potentially 
leading to bradycardia/asystole 2) When the reed switch is closed by the MRI, 
competitive rhythms (fixed pacemaker stimulation in asynchronous mode and intrinsic 
rhythm) may occur with the risk of inducing fatal tachyarrhythmias. 
 The risk of electrical reset is minimized in the new system by reducing MRI induced 
voltage on the leads and improving internal circuit protection.  Even in the theoretical 
case of an electrical reset, an additional safety feature maintains the programmed 
parameter and re-establishes the MRI feature. If programmed parameters can not be 
maintained following a second electrical reset, it will provide asynchronous pacing. 
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Comparison with conventional pacemakers used off-label 
It is notable that in previous studies
5,16
 that performed MRI scans on patients with 
conventional pacemakers in off-label use, cardiac myocardial injury, as indicated by 
increases in PCT and troponin I levels, was not entirely eliminated, even with strict 
precautionary measures to minimize the risk of RF lead heating. This trial showed only 
one increase in PCT from pre- to post-MRI/control visit (control group) >0. 5V out of 
425 leads (0.2%) compared with 6 PCT increases out of 195 leads (3.1%)
16
 and 10 PCT 
increases out of 107 leads (9.4%)
5
 in recent major studies. Furthermore, there were no 
observations of any MRI-induced electrical reset compared with 6% in a previous study
16
 
using conventional pacemakers. Therefore, these specific pulse generator, software and 
lead design changes decrease RF-induced heating and risk of electrical resets due to 
electromagnetic interference, and increase safety for pacemaker patients during MRI 
scanning.  
Limitations 
Use of MRI scanners on pacemaker patients was specifically limited to well-defined 
conditions in the trial and safe use outside of these conditions has not been demonstrated.  
Although there was no indicator of misbehavior of the pacemaker and MRI systems, this 
trial demonstrated safety and efficacy of the device, but did not have the power to look at 
more rare safety events and does not supplant the need for post market surveillance to 
detect unexpected or more rare adverse events.  Finally, tools for monitoring patients in 
the MRI environment precluded a specific evaluation of the electrocardiographic rhythm 
during the MR scan, but visual and verbal monitoring along with pulse oximetry and non 
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invasive blood pressure monitoring were adequate to assess both the pulse rate and the 
overall well being of the patient.  
Conclusion 
MRI scanning of patients with this specific pacemaker system which was evaluated in the 
trial was performed safely with no adverse impact on either the patient or the pacemaker 
system. It is important to note that this safety is conditional upon the use of only this 
complete pacemaker system.  Safety is also conditional upon the pacing system being 
evaluated to assure normal function and appropriate programming, as well as upon 
following specific limitations on the MR scan, including use in a 1.5T MRI scanner and 
specific scan protocols.  This system designed for use in the MRI environment is 
expected to safely facilitate access by pacemaker patients to an increasingly important 
imaging modality. 
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Table 1: Pacing System Integrity Checks 
Pacemaker and both leads implanted > 6 weeks 
Pectoral implantation 
No other active pacing or ICD devices or leads  
No abandoned leads, lead extenders or adapters 
Leads electrically intact and with stable and normal function 
Lead impedance  between 200-1500 ohms 
Capture threshold <2.0V at 0.4 ms 
 
Table 2: Baseline Clinical Characteristics 
Demographic MRI Group 
(n=258) 
Control 
Group 
(n=206) 
Age at Implant 
  Mean + SD 
  Range 
 
69.3 + 12.9 
27.8-95.4 
 
68.0 + 12.6 
19.2-87.3 
Male  
Female 
154 (59.7%) 
104 (40.3%) 
135 (65.5%) 
71 (34.5%) 
Primary indication for implant 
  AV block  
  Sinus node dysfunction 
  Other 
 
95 (36.8%) 
122 (47.3%) 
41 (15.9%) 
 
84 (40.8%) 
90 (43.7%) 
32 (15.5%) 
Atrial Fibrillation/Atrial Flutter/Atrial Tachycardia              130 (50.4%) 82 (39.8%) 
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Figures and Legends: 
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Figure 1: Flowchart of the study.  
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Figure 2: Atrial and ventricular pacing capture thresholds at 0.5ms over time (mean + SD) and changes in 
pacing capture threshold within a group from directly before the MRI/control visit to immediately, 1-week 
and 1-month after MRI/control visit. 
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Figure 3: Changes in atrial and ventricular pacing capture threshold at 0.5ms from 9-12 week visit 
(pre-MRI/pre-control visit) and 1-month post-MRI/post-control visit in each group. 
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Figure 4: Atrial and ventricular sensing (mean + SD) over time, including changes in sensing 
amplitudes within a group directly before the MRI/control visit to immediately, 1-week and 1-month 
after MRI/control visit.  
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Figure 5: Mean + SD atrial and ventricular impedance over time, including changes in lead impedance within 
a group directly before the MRI/control visit to immediately, 1-week and 1-month after MRI/control visit.  
 
 
